INmune Bio

INmune Bio is a clinical-stage immuno-oncology company focused on harnessing the patient's immune system to treat cancer. INKmune, the company’s lead product, activates the patient’s NK cells (natural killer cells) to kill cancer. INmune targets residual disease, which refers to cancer cells that survive initial treatment and return to cause cancer recurrence. By controlling residual disease, patients may live longer. With a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance the ability of NK cells to eliminate residual disease.